Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00304811 · ClinicalTrials.gov registry record · Phase 4

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

A Phase 4 study, sponsored by Michael E. DeBakey VA Medical Center.

Completed
Registry status
Phase 4
Development phase
160
Enrollment target

NCT00304811 is a Phase 4 study that has completed, run by Michael E. DeBakey VA Medical Center. The registered enrollment target is 160 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00304811, a Phase 4 study, has completed, sponsored by Michael E. DeBakey VA Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
160 participants
Enrollment target

Study Summary

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

Interventions

  • DRUG Vancomycin
  • DRUG Vancomycin plus Gentamicin
  • DRUG Vancomycin plus Rifampin
  • DRUG Vancomycin plus Gentamicin plus Rifampin

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2006-01
Est. Completion 2007-01
Phase Phase 4

What the Registry Record Tells You About NCT00304811

The ClinicalTrials.gov registry entry for NCT00304811 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael E. DeBakey VA Medical Center, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Vancomycin is the first listed.

NCT00304811 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00304811 about?

NCT00304811 is a clinical study titled "Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection". The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

What is the current status of trial NCT00304811?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2006-01. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00304811?

The interventions under investigation include: Vancomycin (DRUG), Vancomycin plus Gentamicin (DRUG), Vancomycin plus Rifampin (DRUG), Vancomycin plus Gentamicin plus Rifampin (DRUG).

Who is sponsoring clinical trial NCT00304811?

This trial is sponsored by Michael E. DeBakey VA Medical Center, which has 16 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.